MedTrace Logo

Trial of Artesunate Combination Therapy in Pakistan

NCT00959517 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 588

Last updated 2009-08-14

No results posted yet for this study

Summary

This study is an evaluation of the benefit of adding artesunate to existing first and second line antimalarial therapies in Pakistan.

A placebo controlled trial was carried out to assess two potential benefits of Artesunate Combination Therapy (ACT): efficacy and potential for transmission reduction.

Conditions

  • Uncomplicated Falciparum Malaria

Interventions

DRUG

artesunate (AS)

Recommended dosage over 3 days (for all interventions)

DRUG

sulphadoxine-pyrimethamine (SP)

DRUG

Chloroquine (CQ)

DRUG

primaquine (PQ)

Sponsors & Collaborators

  • HealthNet TPO

    collaborator OTHER

  • London School of Hygiene and Tropical Medicine

    lead OTHER

Principal Investigators

  • Mark W Rowland, PhD · London School of Hygiene and Tropical Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
2 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-07-31
Primary Completion
2005-06-30
Completion
2006-08-31

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00959517 on ClinicalTrials.gov